Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
Follow ATOS
Atossa Therapeutics, Inc. (ATOS) EV/Sales
As of 16 October 2026, Atossa Therapeutics, Inc. (ATOS) trades at a EV/Sales of −7.0×. Over the past ten years it has ranged from −1,350× (December 2022) to 18,049× (March 2015); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2015 | 127× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ATOS Atossa Therapeutics, Inc. | −7.0× |
| PLRZ Polyrizon Ltd. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| BYSI BeyondSpring Inc. compare | 13.8× |
| ABVC ABVC BioPharma, Inc. compare | 19.6× |
| IGC IGC Pharma, Inc. compare | 23.4× |
| MCRB Seres Therapeutics, Inc. compare | 58.8× |
| IBO Impact Biomedical Inc. compare | 881× |
| CYAD Celyad SA compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)